Skip to main content
Top
Published in: Digestive Diseases and Sciences 3/2007

01-03-2007 | Review Paper

The Role of Probiotics in Inflammatory Bowel Disease

Authors: Jennifer L. Jones, Amy E. Foxx-Orenstein

Published in: Digestive Diseases and Sciences | Issue 3/2007

Login to get access

Excerpt

The human intestine contains 300–500 different bacterial species. Concentrations of living bacteria in the large intestine may reach 1011–1012 cells/g of luminal contents [1]. Some of these bacteria are protective, some neutral and others pathogenic [2]. This dynamic community of intestinal microflora plays a critical role in maintaining intestinal health. Metabolic and digestive functions include fermentation of nondigestible dietary residue and mucous, salvage of energy from this residue, production of vitamin K, and absorption of ions. Trophic functions include control of proliferation and differentiation of intestinal epithelial cells, and development and balance of the immune system. These bacteria also protect against pathogens and maintain the epithelial barrier [1]. Probiotics, originally derived from cultured foods and milk products, are viable microorganisms with beneficial physiologic or therapeutic properties [2]. Although the definition of a probiotic has changed many times, a consensus definition term was issued a few years ago. This definition states that “oral probiotics are living microorganisms that, upon ingestion in specific numbers, exert health benefits beyond those of basic nutrition” [3]. Examples of bacteria demonstrated to have beneficial effects include lactic acid bacilli, Lactobacillus, bifidobacterium, Escherichia coli Nissle 1917, Clostridium butyricium, Streptococcus salivarius thermophilus, and a nonpathogenic yeast Saccharomyces boulardii [2, 4]. Mechanisms by which probiotics exert their therapeutic effects include (1) modulation of barrier function, (2) mucosal trophic action, (3) inhibition of pathogenic bacteria, (4) blockade of epithelial attachment and invasion by pathogenic bacteria, (5) modulation of intestinal cytokine production, (6) anti-inflammatory properties, and (7) enhancement of digestion and absorption of food [4, 5]. Properties of an ideal probiotic should include total host safety, resistance to gastric acidity and pancreatic secretions, adherence to epithelial cells, antimicrobial activity, inhibition of pathogenic bacteria, resistance to antibiotics, tolerance to food additives, and stability in food matrix [4]. …
Literature
1.
2.
go back to reference Sartor R (2004) Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 126:1620–1633PubMedCrossRef Sartor R (2004) Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 126:1620–1633PubMedCrossRef
4.
go back to reference Fioramonti J, Theodorou V, Bueno L (2003) Probiotics: what are they? What are their effects on gut physiology? Best Pract Res Clin Gastroenterol 17:711–724PubMedCrossRef Fioramonti J, Theodorou V, Bueno L (2003) Probiotics: what are they? What are their effects on gut physiology? Best Pract Res Clin Gastroenterol 17:711–724PubMedCrossRef
5.
go back to reference Sartor R (2005) Probiotic therapy of intestinal inflammation and infections. Curr Opin Gastroenterol 21:44–50PubMed Sartor R (2005) Probiotic therapy of intestinal inflammation and infections. Curr Opin Gastroenterol 21:44–50PubMed
6.
go back to reference Donohue D, Salminen S, Marteau P (1998) Safety of probiotic bacteria. In: Salminen S, Von Wright A (eds) Lactic acid bacteria. New York, Marcel Decker, pp 369–384 Donohue D, Salminen S, Marteau P (1998) Safety of probiotic bacteria. In: Salminen S, Von Wright A (eds) Lactic acid bacteria. New York, Marcel Decker, pp 369–384
7.
go back to reference Farina C, Arosio M, Mangia M, Moioli F (2001) Lactobacillus casei subsp. rhamnosus sepsis in a patient with ulcerative colitis. J Clin Gastroenterol 33:251–252PubMedCrossRef Farina C, Arosio M, Mangia M, Moioli F (2001) Lactobacillus casei subsp. rhamnosus sepsis in a patient with ulcerative colitis. J Clin Gastroenterol 33:251–252PubMedCrossRef
8.
go back to reference Pletinex M, Legein J, Vandeplas Y (1995) Fungicemia with Saccharomyces boulardii in a 1- year old girl with protracted diarrhea. J Pediatr Gastroenterol Nutr 21:113–115CrossRef Pletinex M, Legein J, Vandeplas Y (1995) Fungicemia with Saccharomyces boulardii in a 1- year old girl with protracted diarrhea. J Pediatr Gastroenterol Nutr 21:113–115CrossRef
9.
go back to reference Fedorak R, Madsen K (2004) Probiotics and the management of inflammatory bowel disease. Inflamm Bowel Dis 10:286–299PubMedCrossRef Fedorak R, Madsen K (2004) Probiotics and the management of inflammatory bowel disease. Inflamm Bowel Dis 10:286–299PubMedCrossRef
10.
go back to reference Riquelme A, Calvo M, Guzman A, Depix M, Garcia P, Perez C, et al. (2003) Saccharomyses cerevaciae fungemia after Saccharomyses boulardii treatment in immunocompromised patients. J Clin Gastroenterol 36:41–43PubMedCrossRef Riquelme A, Calvo M, Guzman A, Depix M, Garcia P, Perez C, et al. (2003) Saccharomyses cerevaciae fungemia after Saccharomyses boulardii treatment in immunocompromised patients. J Clin Gastroenterol 36:41–43PubMedCrossRef
11.
go back to reference Rautio M, Jousimies-Somer H, Kauma H, Pietarinen I, Saxelin M, Tynkkynen S, et al. (1999) Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis 28:1159–1160PubMed Rautio M, Jousimies-Somer H, Kauma H, Pietarinen I, Saxelin M, Tynkkynen S, et al. (1999) Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis 28:1159–1160PubMed
12.
go back to reference Hennequin C, Kauffmann-Lacroix C, Jobert A, Viard J, Ricour C, Jacquemin J, et al. (2000) Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis 19:16–20PubMedCrossRef Hennequin C, Kauffmann-Lacroix C, Jobert A, Viard J, Ricour C, Jacquemin J, et al. (2000) Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis 19:16–20PubMedCrossRef
13.
go back to reference Tamboli C, Caucheteux C, Cortot A, Colombel J, Desreumaux P (2003) Probiotics in inflammatory bowel disease: a critical review. Best Pract Res Clin Gastroenterol 17:805–820PubMedCrossRef Tamboli C, Caucheteux C, Cortot A, Colombel J, Desreumaux P (2003) Probiotics in inflammatory bowel disease: a critical review. Best Pract Res Clin Gastroenterol 17:805–820PubMedCrossRef
14.
go back to reference Salminen M, Tynkkynen S, Rautelin H, Saxelin M, Vaara M, Ruutu P, et al. (2002) Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis 35:1155–1160PubMedCrossRef Salminen M, Tynkkynen S, Rautelin H, Saxelin M, Vaara M, Ruutu P, et al. (2002) Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis 35:1155–1160PubMedCrossRef
15.
go back to reference Hamilton-Miller J, Shah S, Winkler J (1999) Public health issues arising from microbiological and labelling quality foods and supplements containing probiotic organisms. Public Health Nutr 2:223–229PubMedCrossRef Hamilton-Miller J, Shah S, Winkler J (1999) Public health issues arising from microbiological and labelling quality foods and supplements containing probiotic organisms. Public Health Nutr 2:223–229PubMedCrossRef
16.
go back to reference Katz J, Pirovano F, Matteuzzi DEA (2002) Commercially available probiotic preparations: are you getting what you pay for? Gastroenterology 122:A459 Katz J, Pirovano F, Matteuzzi DEA (2002) Commercially available probiotic preparations: are you getting what you pay for? Gastroenterology 122:A459
17.
go back to reference Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, zum Meyer Buschenfelde K (1995) Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD) [see comment]. Clin Exp Immunol 102:448–455PubMedCrossRef Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, zum Meyer Buschenfelde K (1995) Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD) [see comment]. Clin Exp Immunol 102:448–455PubMedCrossRef
18.
go back to reference Macpherson A, Khoo U, Forgacs I, Philpott-Howard J, Bjarnason I (1996) Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 38:365–375PubMed Macpherson A, Khoo U, Forgacs I, Philpott-Howard J, Bjarnason I (1996) Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 38:365–375PubMed
19.
go back to reference Sartor R (2003) Microbial influences in inflammatory bowel disease: role in pathogenesis and clinical implications. In: Sartor R, Sandborn W, eds. Kirsner's Inflammatory Bowel Diseases. 6 ed. Edinburgh, Elsevier, pp 138–162 Sartor R (2003) Microbial influences in inflammatory bowel disease: role in pathogenesis and clinical implications. In: Sartor R, Sandborn W, eds. Kirsner's Inflammatory Bowel Diseases. 6 ed. Edinburgh, Elsevier, pp 138–162
20.
go back to reference Neut C, Bulois P, Desreumaux P, Membre J, Lederman E, Gambiez L, et al. (2002) Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease. Am J Gastroenterol 97:939–946PubMedCrossRef Neut C, Bulois P, Desreumaux P, Membre J, Lederman E, Gambiez L, et al. (2002) Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease. Am J Gastroenterol 97:939–946PubMedCrossRef
21.
go back to reference Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, et al. (2002) Mucosal flora in inflammatory bowel disease. Gastroenterology 122:44–54PubMedCrossRef Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, et al. (2002) Mucosal flora in inflammatory bowel disease. Gastroenterology 122:44–54PubMedCrossRef
22.
go back to reference Cartun R, Van Kruiningen H, Pedersen C, Berman M (1993) An immunocytochemical search for infectious agents in Crohn's disease. Modern Pathol 6:212–219 Cartun R, Van Kruiningen H, Pedersen C, Berman M (1993) An immunocytochemical search for infectious agents in Crohn's disease. Modern Pathol 6:212–219
23.
go back to reference Shanahan F (2000) Probiotics and inflammatory bowel disease: Is there a scientific rationale? Inflamm Bowel Dis 6:107–115PubMedCrossRef Shanahan F (2000) Probiotics and inflammatory bowel disease: Is there a scientific rationale? Inflamm Bowel Dis 6:107–115PubMedCrossRef
24.
go back to reference D’Haens G, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P (1998) Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 114:262–267PubMedCrossRef D’Haens G, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P (1998) Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 114:262–267PubMedCrossRef
25.
go back to reference Rutgeerts P, Van Assche G, Vermeire S, D’Haens G, Baert F, Noman M, et al. (2005) Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 128:856–861PubMedCrossRef Rutgeerts P, Van Assche G, Vermeire S, D’Haens G, Baert F, Noman M, et al. (2005) Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 128:856–861PubMedCrossRef
26.
go back to reference Cario E (2005) Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2. Gut 54:1182–1193PubMedCrossRef Cario E (2005) Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2. Gut 54:1182–1193PubMedCrossRef
27.
go back to reference Buning C, Genschel J, Buhner S, Kruger S, Kling K, Dignass A, et al. (2004) Mutations in the NOD2/CARD15 gene in Crohn's disease are associated with ileocecal resection and are a risk factor for reoperation. Aliment Pharmacol Ther 19:1073–1078PubMedCrossRef Buning C, Genschel J, Buhner S, Kruger S, Kling K, Dignass A, et al. (2004) Mutations in the NOD2/CARD15 gene in Crohn's disease are associated with ileocecal resection and are a risk factor for reoperation. Aliment Pharmacol Ther 19:1073–1078PubMedCrossRef
28.
go back to reference Cobrin G, Abreu M (2005) Defects in mucosal immunity leading to Crohn's disease. Immunol Rev 206:277–295PubMedCrossRef Cobrin G, Abreu M (2005) Defects in mucosal immunity leading to Crohn's disease. Immunol Rev 206:277–295PubMedCrossRef
29.
go back to reference Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, et al. (2000) Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289:1352–1355PubMedCrossRef Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, et al. (2000) Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289:1352–1355PubMedCrossRef
30.
go back to reference Prantera C, Scribano M, Falasco G, Andreoli A, Luzi C (2002) Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 51:405–409PubMedCrossRef Prantera C, Scribano M, Falasco G, Andreoli A, Luzi C (2002) Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 51:405–409PubMedCrossRef
31.
go back to reference Malchow H (1997) Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 25:653–658 Malchow H (1997) Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 25:653–658
32.
go back to reference Guslandi M, Mezzi G, Sorghi M, Testoni P (2000) Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 45:1462–1464PubMedCrossRef Guslandi M, Mezzi G, Sorghi M, Testoni P (2000) Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 45:1462–1464PubMedCrossRef
33.
go back to reference Ingrassia I, Leplingard A, Darfeuille-Michaud A (2005) Lactobacillus casei DN-114 001 inhibits the ability of adherent-invasive Escherichia coli isolated from Crohn's disease to and to invade intestinal epithelial cells. Appl Environ Microbiol 71:2880–2887PubMedCrossRef Ingrassia I, Leplingard A, Darfeuille-Michaud A (2005) Lactobacillus casei DN-114 001 inhibits the ability of adherent-invasive Escherichia coli isolated from Crohn's disease to and to invade intestinal epithelial cells. Appl Environ Microbiol 71:2880–2887PubMedCrossRef
34.
go back to reference Braat H, van den Brande J, van Tol E, Hommes D, Peppelenbosch M, van Deventer S (2004) Lactobacillus rhamnosus induces peripheral hyporesponsiveness in stimulated CD4+ T cells via modulation of dendritic cell function. Am J Clin Nutr 80:1618–1625PubMed Braat H, van den Brande J, van Tol E, Hommes D, Peppelenbosch M, van Deventer S (2004) Lactobacillus rhamnosus induces peripheral hyporesponsiveness in stimulated CD4+ T cells via modulation of dendritic cell function. Am J Clin Nutr 80:1618–1625PubMed
35.
go back to reference Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, et al. (1999) Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 13:1103–1108PubMedCrossRef Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, et al. (1999) Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 13:1103–1108PubMedCrossRef
36.
go back to reference Rembacken B, Snelling A, Hawkey P, Chalmers D, Axon A (1999) Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354(9179):635–639PubMedCrossRef Rembacken B, Snelling A, Hawkey P, Chalmers D, Axon A (1999) Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354(9179):635–639PubMedCrossRef
37.
go back to reference Kruis W, Kalk E, Fric P, et al. (2001) Maintenance of remission in ulcerative colitis is equally effective with Escherichia coli Nissle 1917 and with standard mesalamine. Gastroenterology 120:A127CrossRef Kruis W, Kalk E, Fric P, et al. (2001) Maintenance of remission in ulcerative colitis is equally effective with Escherichia coli Nissle 1917 and with standard mesalamine. Gastroenterology 120:A127CrossRef
38.
go back to reference Schroeder K, Tremaine W, Ilstrup DM (1987) Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis-a randomized study. N Engl J Med 317:1625–1629PubMedCrossRef Schroeder K, Tremaine W, Ilstrup DM (1987) Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis-a randomized study. N Engl J Med 317:1625–1629PubMedCrossRef
39.
go back to reference Baron J, Connell A, Lennard-Jones J (1964) Variation in observers in describing mucosal appearances in proctocolitis. BMJ i:89–92CrossRef Baron J, Connell A, Lennard-Jones J (1964) Variation in observers in describing mucosal appearances in proctocolitis. BMJ i:89–92CrossRef
40.
go back to reference Fedorak R, Gionchetti P, Campieri M (2003) VSL3 probiotic mixture induces remission in patients with active ulcerative colitis (abstr). Gastroenterology 124:A377CrossRef Fedorak R, Gionchetti P, Campieri M (2003) VSL3 probiotic mixture induces remission in patients with active ulcerative colitis (abstr). Gastroenterology 124:A377CrossRef
41.
go back to reference Guslandi M, Giollo P, Testoni P (2003) A pilot trial of saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 15:697–698PubMedCrossRef Guslandi M, Giollo P, Testoni P (2003) A pilot trial of saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 15:697–698PubMedCrossRef
42.
go back to reference Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, et al. (2000) Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119:305–309PubMedCrossRef Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, et al. (2000) Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119:305–309PubMedCrossRef
43.
go back to reference Mimura T, Rizzello F, Schreiber S, et al. (2002) Once daily high dose probiotic therapy maintains remission and improved quality of life in patients with recurrent or refractory pouchitis: a randomized, placebo-controlled, double-blind trial. Gastroenterology 122:A81 Mimura T, Rizzello F, Schreiber S, et al. (2002) Once daily high dose probiotic therapy maintains remission and improved quality of life in patients with recurrent or refractory pouchitis: a randomized, placebo-controlled, double-blind trial. Gastroenterology 122:A81
44.
go back to reference Sandborn W, Tremaine W, Batts K, Pemberton J, Phillips S (1994) Pouchitis after ileal pouch-anal anastomosis: a Pouchitis Disease Activity Index. Mayo Clin Proc 69:409–415PubMed Sandborn W, Tremaine W, Batts K, Pemberton J, Phillips S (1994) Pouchitis after ileal pouch-anal anastomosis: a Pouchitis Disease Activity Index. Mayo Clin Proc 69:409–415PubMed
45.
go back to reference Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers K, Brigidi P, et al. (2003) Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 124:1202–1209PubMedCrossRef Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers K, Brigidi P, et al. (2003) Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 124:1202–1209PubMedCrossRef
46.
go back to reference Shen B, Fazio V, Remzi F, et al. (2005) An open-labeled trial of probiotic as a maintenance therapy in patients with antibiotic-dependent pouchitis. Gastroenterology 124:A586 Shen B, Fazio V, Remzi F, et al. (2005) An open-labeled trial of probiotic as a maintenance therapy in patients with antibiotic-dependent pouchitis. Gastroenterology 124:A586
47.
go back to reference Heuschen U, Autschbach F, Allemeyer E, Zollinger A, Heuschen G, Uehlein T, et al. (2001) Long-term follow-up after ileoanal pouch procedure: algorithm for diagnosis, classification, and management of pouchitis. Dis Colon Rectum 44:487–499PubMedCrossRef Heuschen U, Autschbach F, Allemeyer E, Zollinger A, Heuschen G, Uehlein T, et al. (2001) Long-term follow-up after ileoanal pouch procedure: algorithm for diagnosis, classification, and management of pouchitis. Dis Colon Rectum 44:487–499PubMedCrossRef
48.
go back to reference Shen B, Achkar J, Lashner B, Ormsby A, Remzi F, Bevins C, et al. (2001) Endoscopic and histologic evaluation together with symptom assessment are required to diagnose pouchitis. Gastroenterology 121:261–267PubMedCrossRef Shen B, Achkar J, Lashner B, Ormsby A, Remzi F, Bevins C, et al. (2001) Endoscopic and histologic evaluation together with symptom assessment are required to diagnose pouchitis. Gastroenterology 121:261–267PubMedCrossRef
Metadata
Title
The Role of Probiotics in Inflammatory Bowel Disease
Authors
Jennifer L. Jones
Amy E. Foxx-Orenstein
Publication date
01-03-2007
Published in
Digestive Diseases and Sciences / Issue 3/2007
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-006-9225-y

Other articles of this Issue 3/2007

Digestive Diseases and Sciences 3/2007 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.